title: Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
abstract: OBJECTIVE
  Although it is well known that cisplatin is associated with ototoxicity, there is still a lack of knowledge concerning the ototoxicity of cisplatin, especially in Japanese head and neck cancer patients. The objectives of this study were to determine the incidence rate of cisplatin ototoxicity and to determine the threshold dose causing ototoxicity in the Japanese population.
  
  
  METHODS
  Before-and-after study in a tertiary referral hospital.
  
  
  METHODS
  The distortion product otoacoustic emission (DPOAE) was measured 1 week after each administration of cisplatin in 44 Japanese head and neck cancer patients treated at Kyoto University Hospital. We determined the incidence and threshold dose of cisplatin ototoxicity according to DPOAE data.
  
  
  RESULTS
  The incidence of ototoxicity detected by DPOAE was 77.3%. The average DPOAE value was significantly lower in patients who received more than 200 mg/m(2)  cisplatin than the baseline DPOAE value. The threshold dose for cisplatin ototoxicity was lower in Japanese patients than in European patients.
  
  
  CONCLUSIONS
  Our data suggest that Japanese patients are more susceptible to cisplatin-induced ototoxicity. This is presumably caused by a genetic difference.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan.
authors.forename: Peem
authors.initials: P
authors.lastname: Eiamprapai
authors.forename: Norio
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Harukazu
authors.initials: H
authors.lastname: Hiraumi
authors.forename: Eriko
authors.initials: E
authors.lastname: Ogino-Nishimura
authors.forename: Morimasa
authors.initials: M
authors.lastname: Kitamura
authors.forename: Shigeru
authors.initials: S
authors.lastname: Hirano
authors.forename: Juichi
authors.initials: J
authors.lastname: Ito
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People / Q000706:statistics & numerical data; D001301:Audiometry, Pure-Tone / Q000379:methods; D001309:Auditory Threshold / Q000187:drug effects*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000601:surgery; D034381:Hearing Loss / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects*; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin